Table of Contents Author Guidelines Submit a Manuscript
Volume 23, Issue 1, Pages 51-58

Inclusion compound of Fosinopril with β-cyclodextrin

I. Bratu,1,4 Irina Kacso,1 Gh. Borodi,1 Daniela E. Constantinescu,2 and Felicia Dragan3

1National Institute for R&D of Isotopic and Molecular Technologies, Cluj-Napoca, Romania
2“Terapia-Ranbaxy”, Cluj-Napoca, Romania
3University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania
4National Institute for R&D of Isotopic and Molecular Technologies, P.O. Box 700, RO-400293 Cluj-Napoca, Cluj-Napoca, Romania

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Solid state interactions of bioactive substance (4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxy-propoxy)-(4-phenylbutyl)phosphoryl]acetyl]-pyrrolidine-2-carboxylic acid, called Fosinopril), with β-cyclodextrin (β-CD), the so-called inclusion compounds of a bioactive (cardiovascular) drug is obtained by different preparation methods: kneading, co-precipitation and freeze-drying. The so obtained compounds were investigated by FTIR spectroscopy, X-ray diffraction method, and differential scanning calorimetric measurements (DSC) to evidence their formation. X-ray diffraction patterns show that the inclusion compound was obtained for kneaded, co-precipitation and freeze-dried products. The crystalline/amorphous degree for these compounds was also investigated. Molecular modeling (MM+ molecular mechanics) shows the spatial architecture of the inclusion compound in good agreement with FTIR experimental data: the drug is included with the propanoyloxy-propoxy group inside β-cyclodextrin cavity. These findings may constitute a direct contribution to the molecular encapsulation of Fosinopril into β-cyclodextrin, improving Fosinopril stability and bioavailability of the drug, also.